Evaluation and Management of Precocious Puberty
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Treatment of Peripheral Precocious Puberty
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks Treatment of Peripheral Precocious Puberty Melissa Schoelwer, MD and Erica A Eugster, MD Section of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana Send correspondence to: 705 Riley Hospital Drive, Room 5960 Indianapolis, IN 46202 Phone: 317-944-3889 Fax: 317-944-3882 Email: [email protected] __________________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Schoelwer, M., & Eugster, E. A. (2016). Treatment of Peripheral Precocious Puberty. In Puberty from Bench to Clinic (Vol. 29, pp. 230-239). Karger Publishers. http://dx.doi.org/10.1159/000438895 Peripheral Precocious Puberty Abstract There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and Familial Male-Limited Precocious Puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available. -
Female Tanner Stages (Sexual Maturity Rating)
Strength of Recommendations Preventive Care Visits – 6 to 17 years Bold = Good Greig Health Record Update 2016 Italics = Fair Plain Text = consensus or Selected Guidelines and Resources – Page 3 inconclusive evidence The CRAFFT Screening Interview Begin: “I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your Screening for Major Depressive Disorder -USPSTF answers confidential.” Age 12 years to 18 years 7 to 11 yrs No Yes Part A During the past 12 months did you: Screen (when systems in place for diagnosis, treatment and Insufficient 1. Drink any alcohol (more than a few sips)? □ □ follow-up) evidence 2. Smoked any marijuana or hashish? □ □ Risk factors- parental depression, co-morbid mental health or chronic medical 3. Used anything else to get high? (“anything else” includes illegal conditions, having experienced a major negative life event drugs, over the counter and prescription drugs and things that you sniff or “huff”) □ □ Tools-Patient Health Questionnaire for Adolescent(PHQ9-A) Tools For clinic use only: Did the patient answer “yes” to any questions in Part A? &Beck Depression Inventory-Primary Care version (BDI-PC) perform less No □ Yes □ well Ask CAR question only, then stop. Ask all 6 CRAFFT questions Treatment-Pharmacotherapy – fluoxetine (a SSRI) is Part B Have you ever ridden in a CAR driven by someone □ □ efficacious but SSRIs have a risk of suicidality – consider only (including yourself) who was ‘‘high’’ or had been using if clinical monitoring is possible. Psychotherapy alone or alcohol or drugs? combined with pharmacotherapy can be efficacious. -